225 related articles for article (PubMed ID: 16452237)
1. A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells.
Stallings-Mann M; Jamieson L; Regala RP; Weems C; Murray NR; Fields AP
Cancer Res; 2006 Feb; 66(3):1767-74. PubMed ID: 16452237
[TBL] [Abstract][Full Text] [Related]
2. Targeting the oncogenic protein kinase Ciota signalling pathway for the treatment of cancer.
Fields AP; Frederick LA; Regala RP
Biochem Soc Trans; 2007 Nov; 35(Pt 5):996-1000. PubMed ID: 17956262
[TBL] [Abstract][Full Text] [Related]
3. Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Ciota.
Erdogan E; Lamark T; Stallings-Mann M; Lee Jamieson ; Pellecchia M; Thompson EA; Johansen T; Fields AP
J Biol Chem; 2006 Sep; 281(38):28450-9. PubMed ID: 16861740
[TBL] [Abstract][Full Text] [Related]
4. A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion.
Butler AM; Scotti Buzhardt ML; Erdogan E; Li S; Inman KS; Fields AP; Murray NR
Oncotarget; 2015 Jun; 6(17):15297-310. PubMed ID: 25915428
[TBL] [Abstract][Full Text] [Related]
5. Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer.
Regala RP; Weems C; Jamieson L; Khoor A; Edell ES; Lohse CM; Fields AP
Cancer Res; 2005 Oct; 65(19):8905-11. PubMed ID: 16204062
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-10 is a critical effector of protein kinase Ciota-Par6alpha-mediated lung cancer.
Frederick LA; Matthews JA; Jamieson L; Justilien V; Thompson EA; Radisky DC; Fields AP
Oncogene; 2008 Aug; 27(35):4841-53. PubMed ID: 18427549
[TBL] [Abstract][Full Text] [Related]
7. Ect2 links the PKCiota-Par6alpha complex to Rac1 activation and cellular transformation.
Justilien V; Fields AP
Oncogene; 2009 Oct; 28(41):3597-607. PubMed ID: 19617897
[TBL] [Abstract][Full Text] [Related]
8. Atypical protein kinase Cι (PKCι) promotes metastasis of esophageal squamous cell carcinoma by enhancing resistance to Anoikis via PKCι-SKP2-AKT pathway.
Liu SG; Wang BS; Jiang YY; Zhang TT; Shi ZZ; Yang Y; Yang YL; Wang XC; Lin DC; Zhang Y; Yang H; Cai Y; Zhan QM; Wang MR
Mol Cancer Res; 2011 Apr; 9(4):390-402. PubMed ID: 21310827
[TBL] [Abstract][Full Text] [Related]
9. Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity.
Regala RP; Weems C; Jamieson L; Copland JA; Thompson EA; Fields AP
J Biol Chem; 2005 Sep; 280(35):31109-15. PubMed ID: 15994303
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic activity of Ect2 is regulated through protein kinase C iota-mediated phosphorylation.
Justilien V; Jameison L; Der CJ; Rossman KL; Fields AP
J Biol Chem; 2011 Mar; 286(10):8149-8157. PubMed ID: 21189248
[TBL] [Abstract][Full Text] [Related]
11. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
Puri N; Khramtsov A; Ahmed S; Nallasura V; Hetzel JT; Jagadeeswaran R; Karczmar G; Salgia R
Cancer Res; 2007 Apr; 67(8):3529-34. PubMed ID: 17440059
[TBL] [Abstract][Full Text] [Related]
12. The oncogenic role of PKCiota gene amplification and overexpression in Chinese non-small cell lung cancer.
Luo Q; Tang L; Lin H; Huang J; Zhang T; Liu Y; Wang J; Zhan P; Yin X; Su X; Ji Q; Yu D; Xu L
Lung Cancer; 2014 May; 84(2):190-5. PubMed ID: 24636699
[TBL] [Abstract][Full Text] [Related]
13. Atypical protein kinase C iota expression and aurothiomalate sensitivity in human lung cancer cells.
Regala RP; Thompson EA; Fields AP
Cancer Res; 2008 Jul; 68(14):5888-95. PubMed ID: 18632643
[TBL] [Abstract][Full Text] [Related]
14. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R
Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987
[TBL] [Abstract][Full Text] [Related]
15. Atypical protein kinase C{iota} is required for bronchioalveolar stem cell expansion and lung tumorigenesis.
Regala RP; Davis RK; Kunz A; Khoor A; Leitges M; Fields AP
Cancer Res; 2009 Oct; 69(19):7603-11. PubMed ID: 19738040
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
Imre G; Gekeler V; Leja A; Beckers T; Boehm M
Cancer Res; 2006 May; 66(10):5409-18. PubMed ID: 16707469
[TBL] [Abstract][Full Text] [Related]
17. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide.
Yang L; Mashima T; Sato S; Mochizuki M; Sakamoto H; Yamori T; Oh-Hara T; Tsuruo T
Cancer Res; 2003 Feb; 63(4):831-7. PubMed ID: 12591734
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase Ciota is required for Ras transformation and colon carcinogenesis in vivo.
Murray NR; Jamieson L; Yu W; Zhang J; Gökmen-Polar Y; Sier D; Anastasiadis P; Gatalica Z; Thompson EA; Fields AP
J Cell Biol; 2004 Mar; 164(6):797-802. PubMed ID: 15024028
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesis.
Scotti ML; Bamlet WR; Smyrk TC; Fields AP; Murray NR
Cancer Res; 2010 Mar; 70(5):2064-74. PubMed ID: 20179210
[TBL] [Abstract][Full Text] [Related]
20. The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARgamma pathway.
DeCicco KL; Tanaka T; Andreola F; De Luca LM
Carcinogenesis; 2004 Oct; 25(10):1805-12. PubMed ID: 15205358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
